Cardiovascular drug therapy in elderly patients: Specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations

Drugs and Aging

Volumn 22, Issue 11, 2005, Pages 913-941

  Mangoni, Arduino A ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARDIOVASCULAR AGENT; CARVEDILOL; DIGOXIN; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LABETALOL; LOOP DIURETIC AGENT; LOSARTAN; METOPROLOL; NIFEDIPINE; PERINDOPRIL; POTASSIUM SPARING DIURETIC AGENT; PRAVASTATIN; PROPRANOLOL; RAMIPRIL; SIMVASTATIN; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALSARTAN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE DISEASE; ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; AGING; AREA UNDER THE CURVE; AUTONOMIC NERVOUS SYSTEM FUNCTION; BLEEDING; BRADYCARDIA; BREAST CANCER; CANCER; CHRONIC DISEASE; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; DEHYDRATION; DIABETIC NEPHROPATHY; DIGESTIVE SYSTEM CANCER; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROARRHYTHMIA; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INDUSTRIALIZATION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KIDNEY FAILURE; LIVER DISEASE; LOW DRUG DOSE; MAXIMUM PERMISSIBLE DOSE; MYOPATHY; MYOSITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; PEPTIC ULCER; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIDE EFFECT; STROKE; SURVIVAL RATE; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; VASOCONSTRICTION; VASODILATATION;

AGED; AGED, 80 AND OVER; AGING; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGY; CLINICAL TRIALS; HUMANS;

EID: 28544451832     PISSN: 1170229X     EISSN: 1170229X     Source Type: Journal    
DOI: 10.2165/00002512-200522110-00003     Document Type: Review

References (224)

1. American Heart Association. Heart disease and stroke statistics: 2005 update. Dallas (TX): American Heart Association, 2004
2. Australian Institute of Health and Welfare (AIHW) and Heart Foundation. Heart, stroke and vascular diseases: Australian facts 2004. AIHW Cat. No. CVD 27. Canberra (ACT): Australian Institute of Health and Welfare and the National Heart Foundation of Australia, 2004: 18-26
3. Shah RR. Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II). Br J Clin Pharmacol 2004; 58: 452-69
4. Swift CG. The clinical pharmacology of ageing. Br J Clin Pharmacol 2003; 56: 249-53
5. Routledge PA, O'Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol 2004; 57: 121-6
6. Sokol SI, Cheng A, Frishman WH, et al. Cardiovascular drug therapy in patients with hepatic diseases and patients with congestive heart failure. J Clin Pharmacol 2000; 40: 11-30
7. Matzke GR, Frye RF. Drug administration in patients with renal insufficiency: minimising renal and extrarenal toxicity. Drug Saf 1997; 16: 205-31
8. Vrhovac B, Sarapa N, Bakran I, et al. Pharmacokinetic changes in patients with oedema. Clin Pharmacokinet 1995; 28: 405-18
9. Rodighiero V. Effects of liver disease on pharmacokinetics: an update. Clin Pharmacokinet 1999; 37: 399-431
10. Pichette V, Leblond FA. Drug metabolism in chronic renal failure. Curr Drug Metab 2003; 4: 91-103
11. Barbour MM, McKindley DS. Pharmacology and pharmacotherapy of cardiovascular drugs in patients with chronic renal disease. Semin Nephrol 2001; 21: 66-78
12. Westphal JF, Brogard JM. Drug administration in chronic liver disease. Drug Saf 1997; 17: 47-73
13. Reetze-Bonorden P, Bohler J, Keller E. Drug dosage in patients during continuous renal replacement therapy: pharmacokinetic and therapeutic considerations. Clin Pharmacokinet 1993; 24: 362-79
14. Lakatta EG, Levy D. Arterial and cardiac aging: major share-holders in cardiovascular disease enterprises: Part I. Aging arteries: a 'set up' for vascular disease. Circulation 2003; 107: 139-46
15. Lakatta EG, Levy D. Arterial and cardiac aging: major share-holders in cardiovascular disease enterprises: Part II. The aging heart in health: links to heart disease. Circulation 2003; 107: 346-54
16. Lakatta EG. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III. Cellular and mo-lecular clues to heart and arterial aging. Circulation 2003; 107: 490-7
17. Moore A, Mangoni AA, Lyons D, et al. The cardiovascular system. B J Clin Pharmacol 2003; 56: 254-60
18. Burgess ML, McCrea JC, Hedrick HL. Age-associated changes in cardiac matrix and integrins. Mech Ageing Dev 2001; 122: 1739-56
19. Goor D, Lillehei CW, Edwards JE. The 'sigmoid septum': variation in the contour of the left ventricular outlet. Am J Roentgenol Radium Ther Nucl Med 1969; 107: 366-76
20. Lyons D, Roy S, Patel M, et al. Impaired nitric oxide-mediated vasodilatation and total body nitric oxide production in healthy old age. Clin Sci (Lond) 1997; 93: 519-25
21. Saetrum OO, Ytterberg HT, Saxena PR, et al. Influence of ageing on vasomotor responses of human epicardial coronary arteries. Pharmacol Toxicol 2000; 86: 183-91
22. Andrawis N, Jones DS, Abernethy DR. Aging is associated with endothelial dysfunction in the human forearm vasculature. J Am Geriatr Soc 2000; 48: 193-8
23. Hogikyan RV, Supiano MA. Arterial alpha-adrenergic responsiveness is decreased and SNS activity is increased in older humans. Am J Physiol 1994; 266: E717-24
24. McDonald A, MacDonald E, Fulton JD, et al. No evidence for a general change in contractile responsiveness of the mesenteric artery with aging. J Gerontol A Biol Sci Med Sci 1995; 50A: B20-5
25. Taddei S, Virdis A, Mattei P, et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995; 91: 1981-7
26. Ignarro LJ, Cirino G, Casini A, et al. Nitric oxide as a signaling molecule in the vascular system: an overview. J Cardiovasc Pharmacol 1999; 34: 879-86
27. Ahlers BA, Parnell MM, Chin-Dusting JP, et al. An age-related decline in endothelial function is not associated with alterations in L-arginine transport in humans. J Hypertens 2004; 22: 321-7
28. Kedziora-Kornatowska K, Czuczejko J, Pawluk H, et al. The markers of oxidative stress and activity of the antioxidant system in the blood of elderly patients with essential arterial hypertension. Cell Mol Biol Lett 2004; 9: 635-41
29. Lakatta EG. Cardiovascular reserve capacity in healthy older humans. Aging (Milano) 1994; 6: 213-23
30. Parati G, Frattola A, Di Rienzo M, et al. Effects of aging on 24-h dynamic baroreceptor control of heart rate in ambulant subjects. Am J Physiol 1995; 268: H1606-12
31. Olsen H, Vernersson E, Lanne T. Cardiovascular response to acute hypovolemia in relation to age: implications for orthostasis and hemorrhage. Am J Physiol Heart Circ Physiol 2000; 278: H222-32
32. Rubin PC, Scott PJ, McLean K, et al. Noradrenaline release and clearance in relation to age and blood pressure in man. Eur J Clin Invest 1982; 12: 121-5
33. Sundlof G, Wallin BG. Human muscle nerve sympathetic activity at rest: relationship to blood pressure and age. J Physiol 1978; 274: 621-37
34. Davy KP, Seals DR, Tanaka H. Augmented cardiopulmonary and integrative sympathetic baroreflexes but attenuated peripheral vasoconstriction with age. Hypertension 1998; 32: 298-304
35. Wing LM, Tonkin AL. Orthostatic blood pressure control and ageing. Aust N Z J Med 1997; 27: 462-6
36. Gabbett T, Gass G, Gass E, et al. Norepinephrine and epinephrine responses during orthostatic intolerance in healthy elderly men. Jpn J Physiol 2000; 50: 59-66
37. Stratton JR, Levy WC, Caldwell JH, et al. Effects of aging on cardiovascular responses to parasympathetic withdrawal. J Am Coll Cardiol 2003; 41: 2077-83
38. Ng AV, Callister R, Johnson DG, et al. Sympathetic neural reactivity to stress does not increase with age in healthy humans. Am J Physiol 1994; 267: H344-53
39. O'Mahony D, Bennett C, Green A, et al. Reduced baroreflex sensitivity in elderly humans is not due to efferent autonomic dysfunction. Clin Sci (Lond) 2000; 98: 103-10
40. Taylor JA, Hand GA, Johnson DG, et al. Augmented forearm vasoconstriction during dynamic exercise in healthy older men. Circulation 1992; 86: 1789-99
41. Esler M, Lambert G, Kaye D, et al. Influence of ageing on the sympathetic nervous system and adrenal medulla at rest and during stress. Biogerontology 2002; 3: 45-9
42. Kekki M, Samloff IM, Ihamaki T, et al. Age- and sex-related behaviour of gastric acid secretion at the population level. Scand J Gastroenterol 1982; 17: 737-43
43. Evans MA, Triggs EJ, Cheung M, et al. Gastric emptying rate in the elderly: implications for drug therapy. J Am Geriatr Soc 1981; 29: 201-5
44. Bender AD. The effect of increasing age on the distribution of peripheral blood flow in man. J Am Geriatr Soc 1965; 13: 192-8
45. Corazza GR, Frazzoni M, Gatto MR, et al. Ageing and smallbowel mucosa: a morphometric study. Gerontology 1986; 32: 60-5
46. Gainsborough N, Maskrey VL, Nelson ML, et al. The association of age with gastric emptying. Age Ageing 1993; 22: 37-40
47. Husebye E, Engedal K. The patterns of motility are maintained in the human small intestine throughout the process of aging. Scand J Gastroenterol 1992; 27: 397-404
48. Anantharaju A, Feller A, Chedid A. Aging Liver: a review. Gerontology 2002; 48: 343-53
49. Castleden CM, George CF. The effect of ageing on the hepatic clearance of propranolol. Br J Clin Pharmacol 1979; 7: 49-54
50. Kelly JG, McGarry K, O'Malley K, et al. Bioavailability of labetalol increases with age. Br J Clin Pharmacol 1982; 14: 304-5
51. Davies RO, Gomez HJ, Irvin JD, et al. An overview of the clinical pharmacology of enalapril. Br J Clin Pharmacol 1984; 18 Suppl. 2: 215S-29S
52. Todd PA, Fitton A. Perindopril: a review of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 1991; 42: 90-114
53. Brenner SS, Klotz U. P-glycoprotein function in the elderly. Eur J Clin Pharmacol 2004; 60: 97-102
54. Fulop Jr T, Worum I, Csongor J, et al. Body composition in elderly people: II. Comparison of measured and predicted body composition in healthy elderly subjects. Gerontology 1985; 31: 150-7
55. Fulop Jr T, Worum I, Csongor J, et al. Body composition in elderly people: I. Determination of body composition by multiisotope method and the elimination kinetics of these isotopes in healthy elderly subjects. Gerontology 1985; 31: 6-14
56. Cusack B, Kelly J, O'Malley K, et al. Digoxin in the elderly: pharmacokinetic consequences of old age. Clin Pharmacol Ther 1979; 25: 772-6
57. Fu A, Sreekumaran NK. Age effect on fibrinogen and albumin synthesis in humans. Am J Physiol 1998; 275: E1023-30
58. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002; 71: 115-21
59. Kasiske BL. Relationship between vascular disease and age-associated changes in the human kidney. Kidney Int 1987; 31: 1153-9
60. Back SE, Ljungberg B, Nilsson-Ehle I, et al. Age dependence of renal function: clearance of iohexol and p-amino hippurate in healthy males. Scand J Clin Lab Invest 1989; 49: 641-6
61. Rowe JW, Andres R, Tobin JD, et al. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 1976; 31: 155-63
62. Somogyi A, Hewson D, Muirhead M, et al. Amiloride disposition in geriatric patients: importance of renal function. Br J Clin Pharmacol 1990; 29: 1-8
63. Tsang P, Gerson B. Understanding digoxin use in the elderly patient. Clin Lab Med 1990; 10: 479-92
64. Rigby JW, Scott AK, Hawksworth GM, et al. A comparison of the pharmacokinetics of atenolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young healthy subjects. Br J Clin Pharmacol 1985; 20: 327-31
65. Fliser D, Bischoff I, Hanses A, et al. Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. Eur J Clin Pharmacol 1999; 55: 205-11
66. Mathew TH. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: a position statement. Med J Aust 2005; 183: 138-41
67. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
68. Hallan S, Asberg A, Lindberg M, et al. Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creati-nine assay. Am J Kidney Dis 2004; 44: 84-93
69. Kinirons MT, O'Mahony MS. Drug metabolism and ageing. Br J Clin Pharmacol 2004; 57: 540-4
70. Schmucker DL. Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging 2001; 18: 837-51
71. Miners JO, Penhall R, Robson RA, et al. Comparison of paracetamol metabolism in young adult and elderly males. Eur J Clin Pharmacol 1988; 35: 157-60
72. Greenblatt DJ, Divoll M, Harmatz JS, et al. Oxazepam kinetics: effects of age and sex. J Pharmacol Exp Ther 1980; 215: 86-91
73. Rostami-Hodjegan A, Kroemer HK, Tucker GT. In-vivo indices of enzyme activity: the effect of renal impairment on the assessment of CYP2D6 activity. Pharmacogenetics 1999; 9: 277-86
74. Yuan R, Venitz J. Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs. Int J Clin Pharmacol Ther 2000; 38: 245-53
75. Oberbauer R, Krivanek P, Turnheim K. Pharmacokinetics and pharmacodynamics of the diuretic bumetanide in the elderly. Clin Pharmacol Ther 1995; 57: 42-51
76. Andreasen F, Hansen U, Husted SE, et al. The pharmacokinetics of frusemide are influenced by age. Br J Clin Pharmacol 1983; 16: 391-7
77. Williams RL, Thornhill MD, Upton RA, et al. Absorption and disposition of two combination formulations of hydrochloroth-iazide and triamterene: influence of age and renal function. Clin Pharmacol Ther 1986; 40: 226-32
78. Sabanathan K, Castleden CM, Adam HK, et al. A comparative study of the pharmacokinetics and pharmacodynamics of atenolol, hydrochlorothiazide and amiloride in normal young and elderly subjects and elderly hypertensive patients. Eur J Clin Pharmacol 1987; 32: 53-60
79. Ismail Z, Triggs EJ, Smithurst BA, et al. The pharmacokinetics of amiloride-hydrochlorothiazide combination in the young and elderly. Eur J Clin Pharmacol 1989; 37: 167-71
80. Ho PC, Bourne DW, Triggs EJ, et al. Comparison of plasma levels of canrenone and metabolites after base hydrolysis in young and elderly subjects following single and multiple doses of spironolactone. Eur J Clin Pharmacol 1984; 27: 435-9
81. Andreasen F, Hansen U, Husted SE, et al. The influence of age on renal and extrarenal effects of frusemide. Br J Clin Pharmacol 1984; 18: 65-74
82. Chaudhry AY, Bing RF, Castleden CM, et al. The effect of ageing on the response to frusemide in normal subjects. Eur J Clin Pharmacol 1984; 27: 303-6
83. Wilson TW, McCaulay FA, Waslen TA. Effects of aging on responses to furosemide. Prostaglandins 1989; 38: 675-87
84. Rowlands DB, Glover DR, Young MA, et al. Once daily in-dapamide in the treatment of the elderly and young hypertensive. Eur J Clin Pharmacol 1984; 27: 397-405
85. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97
86. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52
87. Randomised trial of a perindopril-based blood-pressure-lower-ing regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41
88. Fogari R, Zoppi A. Effect of antihypertensive agents on quality of life in the elderly. Drugs Aging 2004; 21: 377-93
89. Waeber B. Very-low-dose combination: a first-line choice for the treatment of hypertension? J Hypertens Suppl 2003; 21 Suppl. 3: S3-10
90. Singh H, Johnson ML. Prescribing patterns of diuretics in multi-drug antihypertensive regimens. J Clin Hypertens (Greenwich) 2005; 7: 81-7
91. Gupta S, Neyses L. Diuretic usage in heart failure: a continuing conundrum in 2005. Eur Heart J 2005; 26: 644-9
92. Gheorghiade M, Filippatos G. Reassessing treatment of acute heart failure syndromes: the ADHERE Registry. Eur Heart J 2005; 7 Suppl. B: B13-9
93. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17
94. Stewart PM. Mineralocorticoid hypertension. Lancet 1999; 353: 1341-7
95. Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351: 33-41
96. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-51
97. Rubin PC, Scott PJ, McLean K, et al. Atenolol disposition in young and elderly subjects. Br J Clin Pharmacol 1982; 13: 235-7
98. Sowinski KM, Forrest A, Wilton JH, et al. Effect of aging on atenolol pharmacokinetics and pharmacodynamics. J Clin Pharmacol 1995; 35: 807-14
99. Gretzer I, Alvan G, Duner H, et al. Beta-blocking effect and pharmacokinetics of pindolol in young and elderly hypertensive patients. Eur J Clin Pharmacol 1986; 31: 415-8
100. Hitzenberger G, Fitscha P, Beveridge T, et al. Effects of age and smoking on the pharmacokinetics of pindolol and propranolol. Br J Clin Pharmacol 1982; 13: 217S-22S
101. Ishizaki T, Hirayama H, Tawara K, et al. Pharmacokinetics and pharmacodynamics in young normal and elderly hypertensive subjects: a study using sotalol as a model drug. J Pharmacol Exp Ther 1980; 212: 173-81
102. Briant RH, Dorrington RE, Ferry DG, et al. Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine. Eur J Clin Pharmacol 1983; 25: 353-6
103. Kendall MJ, Quarterman CP. The effect of age on the pharmacokinetics of oxprenolol. Int J Clin Pharmacol Ther Toxicol 1982; 20: 101-4
104. Quarterman CP, Kendall MJ, Jack DB. The effect of age on the pharmacokinetics of metoprolol and its metabolites. Br J Clin Pharmacol 1981; 11: 287-94
105. Morgan T, Anderson A, Cripps J, et al. Pharmacokinetics of carvedilol in older and younger patients. J Hum Hypertens 1990; 4: 709-15
106. Abernethy DR, Schwartz JB, Plachetka JR, et al. Comparison in young and elderly patients of pharmacodynamics and disposi-tion of labetalol in systemic hypertension. Am J Cardiol 1987; 60: 697-702
107. Rocci Jr ML, Vlasses PH, Cressman MD, et al. Pharmacokinet-ics and pharmacodynamics of labetalol in elderly and young hypertensive patients following single and multiple doses. Pharmacotherapy 1990; 10: 92-9
108. Lalonde RL, Tenero DM, Burlew BS, et al. Effects of age on the protein binding and disposition of propranolol stereoisomers. Clin Pharmacol Ther 1990; 47: 447-55
109. Zhou HH, Whelan E, Wood AJ. Lack of effect of ageing on the stereochemical disposition of propranolol. Br J Clin Pharmacol 1992; 33: 121-3
110. Scott M, Castleden CM, Adam HK, et al. The effect of ageing on the disposition of nifedipine and atenolol. Br J Clin Pharmacol 1988; 25: 289-96
111. Buell JC, Eliot RS, Plachetka JR, et al. Hemodynamic effects of labetalol in young and older adult hypertensives. J Clin Pharmacol 1988; 28: 327-31
112. Tenero DM, Bottorff MB, Burlew BS, et al. Altered beta-adrenergic sensitivity and protein binding to 1-propranolol in the elderly. J Cardiovasc Pharmacol 1990; 16: 702-7
113. Colangelo PM, Blouin RA, Steinmetz JE, et al. Age and beta-adrenergic receptor sensitivity to S(-)- and R,S(+/-)-propranolol in humans. Clin Pharmacol Ther 1992; 51: 549-54
114. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053
115. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-8
116. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7
117. Deedwania PC, Gottlieb S, Ghali JK, et al. Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. Eur Heart J 2004; 25: 1300-9
118. Elliott HL, Meredith PA, Reid JL, et al. A comparison of the disposition of single oral doses of amlodipine in young and elderly subjects. J Cardiovasc Pharmacol 1988; 12 Suppl. 7: S64-6
119. Abernethy DR. An overview of the pharmacokinetics and pharmacodynamics of amlodipine in elderly persons with systemic hypertension. Am J Cardiol 1994; 73: 10A-7A
120. Landahl S, Edgar B, Gabrielsson M, et al. Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients: a comparison with young healthy subjects. Clin Pharmacokinet 1988; 14: 374-83
121. Robertson DR, Waller DG, Renwick AG, et al. Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. Br J Clin Pharmacol 1988; 25: 297-305
122. Abernethy DR, Montamat SC. Acute and chronic studies of diltiazem in elderly versus young hypertensive patients. Am J Cardiol 1987; 60: 116I-20I
123. Montamat SC, Abernethy DR. Calcium antagonists in geriatric patients: diltiazem in elderly persons with hypertension. Clin Pharmacol Ther 1989; 45: 682-91
124. Bianchetti G, Billy S, Ascalone V, et al. Multicenter studies on the pharmacokinetic profile of sustained-release oral diltiazem (300 mg) after once a day repeated administration: influence of age. Int J Clin Pharmacol Ther 1996; 34: 195-201
125. Schwartz JB. Aging alters verapamil elimination and dynamics: single dose and steady-state responses. J Pharmacol Exp Ther 1990; 255: 364-73
126. Schwartz JB, Capili H, Daugherty J. Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1994; 55: 509-17
127. Gupta SK, Atkinson L, Tu T, et al. Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil. Br J Clin Pharmacol 1995; 40: 325-31
128. Sasaki M, Tateishi T, Ebihara A. The effects of age and gender on the stereoselective pharmacokinetics of verapamil. Clin Pharmacol Ther 1993; 54: 278-85
129. Carosella L, Menichelli P, Alimenti M, et al. Verapamil disposition and cardiovascular effects in elderly patients after single intravenous and oral doses. Cardiovasc Drugs Ther 1989; 3: 417-25
130. Ahmed JH, Meredith PA, Elliott HL. The influence of age on the pharmacokinetics of verapamil. Pharmacol Res 1991; 24: 227-33
131. Kloner RA, Sowers JR, DiBona GF, et al. Sex- and age-related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group. Am J Cardiol 1996; 77: 713-22
132. Kuwajima I, Suzuki Y, Shimosawa T, et al. Effect of nifedipine tablets on ambulatory blood pressure in patients aged less than 60 and greater than 65 years with systemic hypertension. Am J Cardiol 1991; 68: 1351-6
133. Grossman E, Messerli FH. Calcium antagonists. Prog Cardiovasc Dis 2004; 47: 34-57
134. Lees KR, Reid JL. Age and the pharmacokinetics and pharmacodynamics of chronic enalapril treatment. Clin Pharmacol Ther 1987; 41: 597-602
135. Lees KR, Green ST, Reid JL. Influence of age on the pharmacokinetics and pharmacodynamics of perindopril. Clin Pharmacol Ther 1988; 44: 418-25
136. MacDonald NJ, Sioufi A, Howie CA, et al. The effects of age on the pharmacokinetics and pharmacodynamics of single oral doses of benazepril and enalapril. Br J Clin Pharmacol 1993; 36: 205-9
137. Hockings N, Ajayi AA, Reid JL. Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat. Br J Clin Pharmacol 1986; 21: 341-8
138. Gautam PC, Vargas E, Lye M. Pharmacokinetics of lisinopril (MK521) in healthy young and elderly subjects and in elderly patients with cardiac failure. J Pharm Pharmacol 1987; 39: 929-31
139. Meyer BH, Muller FO, Badian M, et al. Pharmacokinetics of ramipril in the elderly. Am J Cardiol 1987; 59: 33D-7D
140. Arner P, Wade A, Engfeldt P, et al. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to young and elderly patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1994; 23 Suppl. 4: S44-9
141. Cummings DM, Amadio Jr P, Taylor Jr EJ, et al. The antihyper-tensive response to lisinopril: the effect of age in a predominantly black population. J Clin Pharmacol 1989; 29: 25-32
142. Saalbach R, Wochnik G, Mauersberger H, et al. Antihyperten-sive efficacy, tolerance, and safety of ramipril in young vs old patients: a retrospective study. J Cardiovasc Pharmacol 1991; 18 Suppl. 2: S134-6
143. Bertrand ME. Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. Curr Med Res Opin 2004; 20: 1559-69
144. Dahlof B, Pennert K, Hansson L. Regression of left ventricular hypertrophy: a meta-analysis. Clin Exp Hypertens A 1992; 14: 173-80
145. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273: 1450-6
146. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensinconverting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53
147. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8
148. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583-92
149. Reid JL, Macfadyen RJ, Squire IB, et al. Blood pressure response to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure. Am J Cardiol 1993; 71: 57E-60E
150. Ahmed A. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine? J Am Geriatr Soc 2002; 50: 1297-300
151. Loboz KK, Shenfield GM. Drug combinations and impaired renal function: the 'triple whammy'. Br J Clin Pharmacol 2005; 59: 239-43
152. Bicket DP. Using ACE inhibitors appropriately. Am Fam Physician 2002; 66: 461-8
153. Packer M, Poole-Wilson PA, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure: ATLAS Study Group. Circulation 1999; 100: 2312-8
154. Massie BM, Armstrong PW, Cleland JG, et al. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. Arch Intern Med 2001; 161: 165-71
155. Manyemba J, Mangoni AA, Pettingale KW, et al. Determinants of failure to prescribe target doses of angiotensin-converting enzyme inhibitors for heart failure. Eur J Heart Fail 2003; 5: 693-6
156. Tenero DM, Martin DE, Miller AK, et al. Effect of age and gender on the pharmacokinetics of eprosartan. Br J Clin Pharmacol 1998; 46: 267-70
157. Vachharajani NN, Shyu WC, Smith RA, et al. The effects of age and gender on the pharmacokinetics of irbesartan. Br J Clin Pharmacol 1998; 46: 611-3
158. Vachharajani NN, Shyu WC, Smith RA. The effect of age on the pharmacokinetics of irbesartan [abstract]. J Clin Pharmacol 1997; 37: 872
159. Sioufi A, Marfil F, Jaouen A, et al. The effect of age on the pharmacokinetics of valsartan. Biopharm Drug Dispos 1998; 19: 237-44
160. Meier P, Maillard M, Burnier M. The future of angiotensin II inhibition in cardiovascular medicine. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5: 15-30
161. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001; 103: 904-12
162. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial: the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-7
163. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabe-tes and nephropathy. N Engl J Med 2004; 351: 1952-61
164. Lee VC, Rhew DC, Dylan M, et al. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004; 141: 693-704
165. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-75
166. Baruch L, Glazer RD, Aknay N, et al. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (ValHeFT). Am Heart J 2004; 148: 951-7
167. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-71
168. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-6
169. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-81
170. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-66
171. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752-60
172. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003
173. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hyperten-sion: is it a wise choice? Lancet 2004; 364: 1684-9
174. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-86
175. Sica DA. The practical aspects of combination therapy with angiotensin receptor blockers and angiotensin-converting enzyme inhibitors. J Renin Angiotensin Aldosterone Syst 2002; 3: 66-71
176. Jacobsen P, Parving HH. Beneficial impact on cardiovascular risk factors by dual blockade of the renin-angiotensin system in diabetic nephropathy. Kidney Int Suppl 2004; 92: S108-10
177. Doulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005; 45: 880-6
178. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-906
179. Roberto P, Vitaliano B, Donatella P, et al. Disopyramide pharmacokinetics in the elderly after single oral administration. Pharmacol Res Commun 1988; 20: 1025- 34
180. Bonde J, Pedersen LE, Bodtker S, et al. The influence of age and smoking on the elimination of disopyramide. Br J Clin Pharmacol 1985; 20: 453-8
181. Cusack B, Kelly JG, Lavan J, et al. Pharmacokinetics of lignocaine in the elderly [proceedings]. Br J Clin Pharmacol 1980; 9: 293P-4P
182. Ochs HR, Greenblatt DJ, Woo E, et al. Reduced quinidine clearance in elderly persons. Am J Cardiol 1978; 42: 481-5
183. Nation RL, Triggs EJ, Selig M. Lignocaine kinetics in cardiac patients and aged subjects. Br J Clin Pharmacol 1977; 4: 439-48
184. Grech-Belanger O, Barbeau G, Kishka P, et al. Pharmacokinetics of mexiletine in the elderly. J Clin Pharmacol 1989; 29: 311-5
185. el Allaf D, Carlier J, Dresse A. Effects of age on the pharmacokinetics of mexiletine. Int J Clin Pharmacol Res 1986; 6: 303-7
186. White M, Leenen FH. Effects of age on cardiovascular re-sponses to adrenaline in man. Br J Clin Pharmacol 1997; 43: 407-14
187. Rashid MU, Bateman DN. Effect of intravenous atropine on gastric emptying, paracetamol absorption, salivary flow and heart rate in young and fit elderly volunteers. Br J Clin Pharmacol 1990; 30: 25-34
188. van Brummelen P, Buhler FR, Kiowski W, et al. Age-related decrease in cardiac and peripheral vascular responsiveness to isoprenaline: studies in normal subjects. Clin Sci (Lond) 1981; 60: 571-7
189. White M, Fourney A, Leenen FH. Age, hypertension, and cardiac responses to beta-agonist in humans. Clin Pharmacol Ther 1998; 63: 663-71
190. Klein C, Hiatt WR, Gerber JG, et al. Age does not alter human vascular and nonvascular beta 2-adrenergic responses to isoproterenol. Clin Pharmacol Ther 1988; 44: 573-8
191. Fang MC, Stafford RS, Ruskin JN, et al. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med 2004; 164: 55-60
192. Wellens HJ. Cardiac arrhythmias: the quest for a cure: a histori-cal perspective. J Am Coll Cardiol 2004; 44: 1155-63
193. Smith NL, Chan JD, Rea TD, et al. Time trends in the use of beta-blockers
194. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289: 871-8
195. Martin PD, Dane AL, Nwose OM, et al. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J Clin Pharmacol 2002; 42: 1116-21
196. Gibson DM, Bron NJ, Richens A, et al. Effect of age and gender on pharmacokinetics of atorvastatin in humans. J Clin Pharmacol 1996; 36: 242-6
197. Cheng H, Rogers JD, Sweany AE, et al. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. Pharm Res 1992; 9: 1629-33
198. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-lower-ing therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997; 96: 4211-8
199. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
200. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996; 335: 1001-9
201. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-57
202. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised pla-cebo-controlled trial. Lancet 2002; 360: 7-22
203. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-30
204. Roberts MS, Rumble RH, Wanwimolruk S, et al. Pharmacokinetics of aspirin and salicylate in elderly subjects and in patients with alcoholic liver disease. Eur J Clin Pharmacol 1983; 25: 253-61
205. Ho PC, Triggs EJ, Bourne DW, et al. The effects of age and sex on the disposition of acetylsalicylic acid and its metabolites. Br J Clin Pharmacol 1985; 19: 675-84
206. Cuny G, Royer RJ, Mur JM, et al. Pharmacokinetics of salicy-lates in elderly. Gerontology 1979; 25: 49-55
207. Denninger MH, Necciari J, Serre-Lacroix E, et al. Clopidogrel antiplatelet activity is independent of age and presence of atherosclerosis. Semin Thromb Hemost 1999; 25 Suppl. 2: 41-5
208. Shah J, Teitelbaum P, Molony B, et al. Single and multiple dose pharmacokinetics of ticlopidine in young and elderly subjects. Br J Clin Pharmacol 1991; 32: 761-4
209. Shepherd AM, Hewick DS, Moreland TA, et al. Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol 1977; 4: 315-20
210. Barrett JS, Gibiansky E, Hull RD, et al. Population pharmacody namics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. Int J Clin Pharmacol Ther 2001; 39: 431-46
211. Modi NB, Fox NL, Clow FW, et al. Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction. J Clin Pharmacol 2000; 40: 508-15
212. Siguret V, Pautas E, Fevrier M, et al. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 2000; 84: 800-4
213. Garcia Rodriguez LA, Hernandez-Diaz S. Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol 2004; 159: 23-31
214. Guslandi M, Pellegrini A, Sorghi M. Gastric mucosal defences in the elderly. Gerontology 1999; 45: 206-8
215. Pilotto A, Franceschi M, Leandro G, et al. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004; 20: 1091-7
216. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in pa-tients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-33
217. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502
218. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-89
219. Pineo GF, Hull RD. Low-molecular-weight heparin for the treatment of venous thromboembolism in the elderly. Clin Appl Thromb Hemost 2005; 11: 15-23
220. Haas S. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes. Semin Vasc Med 2003; 3: 139-46
221. Saigo M, Hsue PY, Waters DD. Role of thrombotic and fibrinolytic factors in acute coronary syndromes. Prog Cardiovasc Dis 2004; 46: 524-38
222. Cohen N, Almoznino-Sarafian D, Alon I, et al. Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. Stroke 2000; 31: 1217-22
223. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001; 38: 1231-66
224. Australian Institute of Health and Welfare (AIHW). Australian Population Patterns and Implications: AIHW Cat. No. DIS-19. Canberra (ACT): Australian Institute of Health and Welfare, 2000: 1-7